The role of caveolin-1 in androgen insensitive prostate cancer

Journal of Urology

Volumn 168, Issue 4 I, 2002, Pages 1589-1596

  Mouraviev, Vladimir ^a   Li, Likun ^a   Tahir, Salahaldin A ^a   Yang, Guang ^a   Timme, Terry L ^a   Goltsov, Alexei ^a   Ren, Chengzhen ^a   Satoh, Takefumi ^a   Wheeler, Thomas M ^a   Ittmann, Michael M ^a   Miles, Brian J ^a   Amato, Robert J ^a   Kadmon, Dov ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Androgens; Caveolins; Neoplasm metastasis; Prostate; Prostatic neoplasms

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; LIPID;

ANDROGEN INSENSITIVITY SYNDROME; ARTICLE; CAVEOLA; HUMAN; LIPID TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SERUM; SIGNAL TRANSDUCTION;

EID: 0036784311     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)64526-0     Document Type: Article

References (78)

1. Epidemiology of prostate cancer
2. Cancer statistics, 2001
3. Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
4. Cancer surveillance series: Interpreting trends in prostate cancer - Part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality
5. Cancer surveillance series: Interpreting trends in prostate cancer - Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality
6. Prostate cancer: Numbers may not tell the whole story
7. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?
8. Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome
9. Histologic grading and clinical staging of prostatic carcinoma
10. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
11. Natural history of low-stage prostatic cancer and the impact of early detection
12. Allelic loss in locally metastatic, multisampled prostate cancer
13. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization
14. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer
15. Combined androgen blockade: The gold standard for metastatic prostate cancer
16. A prospective randomized trial for treating stages B2 and C prostate cancer: Radical surgery or irradiation with neoadjuvant endocrine therapy
17. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer
18. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
19. In situ gene therapy for prostate cancer: Immunomodulatory approaches
20. The role of p53 in prostate cancer progression
21. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
22. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer
23. HER2 in prostate cancer: A viable target or innocent bystander?
24. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
25. Genetic alterations in hormone-refractory recurrent prostate carcinomas
26. The expression of drug resistance gene products during the progression of human prostate cancer
27. Elevated expression of caveolin is associated with prostate and breast cancer
28. Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker
29. Elevated caveolin-1 levels in African-American versus white-American prostate cancer
30. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells
31. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer
32. Hypermethylation of the caveolin-1 gene promoter in prostate cancer
33. Caveolin-1 expression is associated with high-grade bladder cancer
34. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity
35. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: Overexpression of oncogene MET correlates with tumor differentiation in ESCC
36. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage
37. Caveolin-1 is regulated by c-myc and suppresses c-mycinduced apoptosis
38. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling
39. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells
40. Caveolin-1, a putative tumour suppressor gene
41. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth
42. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells
43. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism
44. Spontaneous but not experimental metastatic activities differentiate primary tumorderived vs metastasis-derived mouse prostate cancer cell lines
45. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers
46. Review of allelic loss and gain in prostate cancer
47. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines
48. Caveolin-3 in muscular dystrophy
49. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy
50. Invasion activating caveolin-1 mutation in human schirrhous breast cancer
51. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice
52. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities
53. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae
54. Caveolin-1: A complex and provocative therapeutic target in prostate cancer and potentially other malignancies
55. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival
56. Expression level of Bcl-2 determines antior proapoptotic function
57. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells
58. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells
59. Molecular pathways underlying prostate cancer progression: The role of caveolin-1
60. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
61. Ligand-independent activation of steroid hormone receptors
62. Regulation of prostatic growth and function by peptide growth factors
63. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
64. Elevation of cyclic adenosine 3′, 5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells
65. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes
66. Isolated endosomes from quiescent rat liver contain the signal transduction machinery. Differential distribution of activated Raf-1 and Mek in the endocytic compartment
67. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
68. Abrogation of c-Raf expression induces apoptosis in tumor cells
69. Caveolin-1 interacts with androgen receptor
70. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling, caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha
71. The adaptor protein Shc couples a class of integrins to the control of cell cycle progression
72. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth
73. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression
74. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state
75. Critical factors in the biology of human cancer metastasis: Twenty-eighth G. H. A. Clowes memorial award lecture
76. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells
77. Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria
78. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression